Summary of Significant Accounting Policies (Tables)

3 Months Ended

Mar. 31, 2026

Accounting Policies [Abstract]

Schedule of Reconciliation of the Company's Net Loss

The following table presents the significant segment expenses regularly provided to the CODM and a reconciliation to net loss (in thousands):

	Three Months Ended March 31,
	2026			2025
General and administrative expenses	$	7,459		$	3,008
Research and development expenses
Schizophrenia programs		5,813			1,260
Bipolar depression programs		3,006			—
Formulation and CMC		2,329			653
Preclinical and other direct expenses		501			—
Total direct research and development expenses		11,649			1,913
Personnel-related		2,115			1,253
Consulting and other		881			255
Total indirect and unallocated research and development expenses		2,996			1,508
Total research and development expenses		14,645			3,421
Total operating loss		(22,104	)		(6,429	)
Non-operating income		3,050			1,123
Net loss	$	(19,054	)	$	(5,306	)